Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says

Published 1 month ago Positive
Johnson & Johnson, Protagonist Therapeutics' Icotrokinra Shows Potential Across Autoimmune Indications, Wedbush Says
Auto
Icotrokinra, an oral interleukin-23 antagonist peptide being developed by Protagonist Therapeutics (

PREMIUM

Upgrade to read this MT Newswires article and get so much more.

A Silver or Gold subscription plan is required to access premium news articles.

Upgrade

Already have a subscription? Sign in

More News

Ensurge Micropower ASA - Key information relating to possible repair issue/subsequent offering

17 minutes ago Positive

Ensurge Micropower ASA – Private Placement successfully placed

21 minutes ago Positive

Baxdrostat demonstrated a statistically significant and highly clinically meaningful placebo-adjusted reduction of 14.0 mmHg in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension in the Bax24 Phase III trial

35 minutes ago Positive

ANZ profit falls short as CEO Nuno Matos pushes for turnaround

45 minutes ago Positive

New REDUCE-IT® Aspirin Analysis Presented at AHA Scientific Sessions 2025 Reinforces VASCEPA®/VAZKEPA® (Icosapent Ethyl) Reduced Cardiovascular Events in High-Risk Patients

53 minutes ago Positive